Skip to main content
Evidence-Based Supplement Research
Evidence-Based Supplement Research
Pillser
Search
Sign UpLog In

Impact of probiotic supplementation in a patient with type 2 diabetes on glycemic and lipid profile.

  • 2022-06
  • Clinical nutrition ESPEN 49
    • Maíra Corneli Ziegler
    • Emílio Ernesto Garbim Junior
    • Viviane Schimitt Jahnke
    • Josué Guilherme Lisbôa Moura
    • Carolina Serpa Brasil
    • Pedro Henrique Schimitt da Cunha
    • Priscila Schimitt Lora
    • Tanise Gemelli

Study Design

Type
Clinical Trial
Sample size
n = 20
Population
20 patients aged >30 years with T2DM who were overweight or obese
Methods
Before-and-after clinical trial; patients administered probiotic supplements (Bacillus clausii) daily for 90 days; evaluated blood glucose, lipid and intestinal microbiota profiles, blood pressure, drug therapy, BMI, and food tissue
Duration
90 days
Funding
Unclear

Background & aims

Type 2 diabetes mellitus (T2DM) is a progressive chronic non-communicable disease associated with various comorbidities; it is considered complex and therefore multifactorial strategies must be applied to reduce the associated risks. The aim of this before-and-after clinical trial was to evaluate the effects of adjuvant supplementation with probiotics in patients with T2DM.

Methods

The study included 20 patients aged >30 years with T2DM who were overweight or obese. The patients were administered probiotic supplements daily for 90 days, which consisted of probiotics Bacillus clausii microorganism strain. The patients' blood glucose parameters, lipid and intestinal microbiota profiles, blood pressure (BP), drug therapy, body mass index (BMI), and food tissue were evaluated.

Results

At the end of the study, we observed a statistically significant difference in blood glucose, increased high density lipoprotein (HDL) plasma levels, and improved intestinal microbiota profiles among the patients included in this study.

Conclusions

The results showed that probiotic supplementation significantly reduced fasting glycemia and promoted an improvement in their lipid profiles and intestinal health. These findings are promising and the use of probiotics may be an appropriate adjuvant therapy for glycemic control in patients with T2DM.

Research Insights

Back to top